Verrica Pharmaceuticals Inc.
Business
Verrica Pharmaceuticals is a therapeutics company developing and commercializing medications for dermatologic diseases, including skin cancers. Its commercial product YCANTH (VP-102), a proprietary drug-device combination of cantharidin approved by the FDA in July 2023, treats molluscum contagiosum in pediatric and adult patients. The company is developing YCANTH for common warts and VP-315, an oncolytic peptide-based injectable therapy, for basal cell carcinoma. Verrica commercializes through a specialized U.S. sales force targeting dermatologists and pediatricians, and has licensed rights to Torii Pharmaceutical for Japan and in-licensed VP-315 from Lytix BioPharma.
Summary from 10-K filed 2026-03-11
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 36 | 8 | — | — | — | |
| Cost of product revenue | 2 | 2 | 289,000 | 0 | — | |
| Cost of license and collaboration revenue | 1 | 887,000 | — | — | — | |
| Selling, general and administrative | 35 | 59 | 47 | 17 | — | |
| Research and development | 9 | 12 | 20 | 12 | 16 | |
| Loss on disposal of equipment | 200,000 | 100,000 | 3 | 0 | — | |
| Total operating expenses | 48 | 73 | 71 | 30 | 43 | |
| Loss from operations | −12 | −66 | −66 | −21 | −31 | |
| Interest income | 929,000 | 1 | 3 | 476,000 | 123,000 | |
| Interest expense | −8 | −9 | −4 | — | — | |
| Change in fair value of derivative liability | 3 | −3 | 0 | — | — | |
| Loss on extinguishment of debt | −2 | 0 | 0 | −1 | 0 | |
| Other expense | −3,000 | −17,000 | −14,000 | −58,000 | 0 | |
| Total other expense, net | −6 | −11 | −1 | −3 | −4 | |
| Net loss | −18 | −77 | −67 | −24 | −35 | |
| Net loss per share, basic (in shares) | −1.68 | −14.78 | −1.48 | −0.72 | −1.3 | |
| Net loss per share, diluted (in shares) | −1.68 | −14.78 | −1.48 | −0.72 | −1.3 | |
| Weighted-average common shares outstanding, basic (in dollars per share) | 11 | 5 | 45 | 34 | 27 | |
| Weighted-average common shares outstanding, diluted (in dollars per share) | 11 | 5 | 45 | 34 | 27 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 30 | 46 | 70 | 34 | 16 | |
| Accounts receivable | 5 | 48,000 | 4 | 0 | — | |
| Collaboration revenue, billed and unbilled | 137,000 | 29,000 | — | — | — | |
| Deferred R&D services, current portion (Note 12) | 2 | 0 | — | — | — | |
| Inventory | 2 | 2 | 1 | 0 | — | |
| Prepaid expenses and other current assets | 3 | 2 | 3 | 4 | 4 | |
| Total current assets | 43 | 51 | 78 | 39 | 74 | |
| Property and equipment, net | 209,000 | 589,000 | 1 | 4 | 4 | |
| Operating lease right-of-use asset | 540,000 | 836,000 | 1 | 1 | 2 | |
| Finance lease right-of-use asset | 1 | 1 | 1 | 0 | — | |
| Deferred R&D services, non-current portion (Note 12) | 2 | 0 | — | — | — | |
| Other non-current assets | 376,000 | 376,000 | 452,000 | 276,000 | 295,000 | |
| Total assets | 47 | 54 | 82 | 45 | 80 | |
| Accounts payable | 2 | 2 | 2 | 507,000 | 845,000 | |
| Accrued expenses and other current liabilities | 13 | 14 | 14 | 3 | 3 | |
| Deferred revenue | 782,000 | 0 | — | — | — | |
| Current portion of long-term debt | 0 | 13 | 0 | — | — | |
| Operating lease liability | 341,000 | 315,000 | 324,000 | 297,000 | 245,000 | |
| Finance lease liability | 405,000 | 352,000 | 376,000 | 0 | 6,000 | |
| Total current liabilities | 16 | 29 | 17 | 3 | 46 | |
| Operating lease liability | 242,000 | 583,000 | 910,000 | 1 | 1 | |
| Finance lease liability | 643,000 | 768,000 | 1 | 0 | 16,000 | |
| Derivative liability | 0 | 3 | 0 | — | — | |
| R&D Funding Liability (Note 12) | 5 | 0 | — | — | — | |
| Long-term debt | 0 | 31 | 43 | 0 | — | |
| Total liabilities | 22 | 64 | 62 | 5 | 48 | |
| Commitments and Contingencies (Note 6) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 200,000,000 authorized; 17,189,300 shares issued and 17,178,786 shares outstanding as of December 31, 2025 and 9,188,513 shares issued and 9,177,999 shares outstanding as of December 31, 2024 | 2,000 | 1,000 | 4,000 | 4,000 | 3,000 | |
| Treasury stock, at cost, 10,514 shares as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Additional paid-in capital | 350 | 297 | 250 | 203 | 172 | |
| Accumulated deficit | −325 | −307 | −230 | −163 | −139 | |
| Total stockholders (deficit) equity | 25 | −10 | 20 | 40 | 33 | |
| Total liabilities and stockholders (deficit) equity | 47 | 54 | 82 | 45 | 80 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 3 | 7 | 14 | 5 | 6 | |
| Depreciation expense | 100,000 | 300,000 | 500,000 | 500,000 | 244,000 | |
| Non-cash interest expense | 2 | 2 | 810,000 | 383,000 | 1 | |
| Loss on disposal of fixed assets | 246,000 | 83,000 | 3 | 0 | — | |
| Amortization of operating lease right-of-use asset | 296,000 | 308,000 | 286,000 | 264,000 | 228,000 | |
| Amortization of finance lease right-of-use asset | 352,000 | 619,000 | 20,000 | 0 | — | |
| Change in obligation for R&D Funding liability | 754,000 | 0 | — | — | — | |
| Non-cash R&D expense related to warrant vesting | 51,000 | 0 | — | — | — | |
| Impairment of right-of-use asset | 0 | 255,000 | 0 | — | — | |
| Loss on termination of financing lease | 1,000 | 19,000 | 0 | 6,000 | 0 | |
| Prepaid expenses and other assets | −264,000 | −1 | 587,000 | −456,000 | −543,000 | |
| Deferred revenue | 782,000 | 0 | — | — | — | |
| Accounts payable | 176,000 | −568,000 | 2 | −338,000 | 497,000 | |
| Accounts receivable | −5 | 4 | −4 | 0 | — | |
| Collaboration receivable, billed and unbilled | −108,000 | 139,000 | — | — | — | |
| Accrued expenses and other current liabilities | −1 | −294,000 | 11 | −255,000 | 208,000 | |
| Operating lease liability | −315,000 | −322,000 | −291,000 | −264,000 | −197,000 | |
| Net cash used in operating activities | −18 | −61 | −39 | −19 | −28 | |
| Purchases of property and equipment | 0 | −27,000 | −362,000 | −302,000 | −883,000 | |
| Sale of fixed assets | 0 | 8,000 | 0 | — | — | |
| Net cash used in investing activities | 0 | −19,000 | −362,000 | 54 | −998,000 | |
| Proceeds from exercise of stock options | 0 | 155,000 | 7,000 | 0 | 558,000 | |
| Proceeds from issuance of debt, net of issuance costs | 0 | 0 | 44 | 0 | 5 | |
| Proceeds from issuance of common stock, pre-funded warrants and warrants | 50 | 43 | — | — | — | |
| Issuance costs for common stock, pre-funded warrants and warrants | −310,000 | −3 | −177,000 | 0 | — | |
| Cash paid to settle debt | −35 | 0 | — | — | — | |
| Repayment of debt | −13 | 0 | 0 | −44 | 0 | |
| Debt amendment costs | −110,000 | −1 | 0 | — | — | |
| Repayment of finance lease | −383,000 | −924,000 | −23,000 | −4,000 | −5,000 | |
| Net cash provided by financing activities | 1 | 38 | 74 | −17 | 34 | |
| Net decrease in cash and cash equivalents | −16 | −23 | 35 | 19 | 5 | |
| Cash paid for interest | 5 | 7 | 3 | 2 | 3 | |
| Recognition of R&D funding liability and deferred R&D services | 5 | 0 | — | — | — | |
| Non-cash accruals for equity issuance costs | 637,000 | 0 | — | — | — | |
| Right-of-use asset obtained in exchange for lease obligation | 302,000 | 2 | 1 | 99,000 | 0 | |
| Extinguishment of finance lease liability as a result of lease termination | 71,000 | 2 | — | — | — | |
| Extinguishment of operating lease liability as a result of lease termination | 0 | 14,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Verrica Pharmaceuticals Inc.'s CIK number?
Verrica Pharmaceuticals Inc.'s SEC CIK number is 0001660334 (1660334). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Verrica Pharmaceuticals Inc.'s SEC filings?
All of Verrica Pharmaceuticals Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Verrica Pharmaceuticals Inc. last report earnings?
Verrica Pharmaceuticals Inc. (VRCA) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-219395). This is Verrica Pharmaceuticals Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Verrica Pharmaceuticals Inc.'s most recent earnings 8-K?
Verrica Pharmaceuticals Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-219395. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Verrica Pharmaceuticals Inc.'s latest earnings 8-K →
Look up any company's CIK number →